Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
A patient who presents for AOD-9604 as a perceived "milder" or "more natural" alternative to approved GLP-1 receptor agonists is still a patient who needs a validated depression screen (PHQ-A for adolescents), an Eating Disorder Examination Questionnaire, and a conversation about body image expectations
No Padded Panels Hormones, metabolic, inflammatory, micronutrient, cardiovascular measured, not derived
Topical application of GHK-Cu accelerates wound closure (full-thickness excisional wounds in rodents, wound area tracing, digital planimetry), increases granulation tissue thickness (H&E histology), promotes re-epithelialisation (K14/K5 basal keratinocyte IHC, Ki-67 proliferation), and reduces scar width and fibrosis (Massons trichrome, collagen bundle organisation by SHG microscopy)
Medically reviewed by: Jayden Lee, PharmD, EMBA Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes
